Clarivate Introduces Epidemiology Intelligence™ for Precision Patient Population Analysis

May 07, 2024 05:00 PM AEST | By Cision
 Clarivate Introduces Epidemiology Intelligence™ for Precision Patient Population Analysis
Image source: Kalkine Media

Empowering biopharma with unified epidemiology, incidence and prevalence data alongside claims-based population insights, for precise market sizing and patient population analysis

LONDON, May 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligence™. The new solution combines rich insights from epidemiology, incidence and prevalence database solutions. It includes U.S. claims-based population insights to empower biopharma companies to accurately gauge market size and target patient demographics with ease.

In today's rapidly evolving market landscape, precise forecasting is essential for biopharmaceutical companies. Yet, traditional research methods often come with limitations that can lead to inaccurate estimations and costly consequences. Epidemiology Intelligence empowers users with unique insights to address critical questions about the drug-treatable population. The solution facilitates precise assessments, identification of niche populations and accurate predictions based on population insights.

Ravindra Sharma, VP Product Management, Clarivate, said: "The launch of Epidemiology Intelligence marks a significant milestone for Clarivate in our ongoing commitment to deliver comprehensive and actionable solutions to life sciences and healthcare companies. Clients can now access comprehensive coverage of disease epidemiology paired with expert analysis, seamlessly integrated into a unified platform. The new solution enables them to deliver safe, effective and commercially successful treatments to patients faster."

Epidemiology Intelligence accelerates data-driven decision-making across the drug development lifecycle. Clients can benchmark market forecasts, validate investments, pinpoint growth opportunities and utilize the solution to strategically position their products for success.

To learn more about Epidemiology Intelligence, visit here.

About Epidemiology Intelligence

Epidemiology Intelligence is a new, unified Clarivate patient population offering that brings together our legacy Epidemiology and Incidence and Prevalence Database solutions, as well as claims-based population insights, on a single platform. This transformative solution offers user-friendly visualizations, easy data exports and a unique breadth and depth of patient population insights. Conduct thorough market assessment with comprehensive coverage across 1200+ diseases and procedures. Dive deep into expert disease-specific epidemiology analysis and 10 and 20-year forecasts across 220 indications and over 5000 patient populations. Leverage expanded patient segmentation and location granularity with insights sourced from Clarivate U.S. Real-World Data.

About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com

Media Contact:
Catherine Daniel
Director External Communications, Life Sciences & Healthcare
[email protected]

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.